In total, 1386 paraffin embedded radical prostatectomy specimens from patients with clinically localized prostate cancer (PCa) excised between 2002–06 were analyzed. Pathologic assessment paid particular attention to laterality and percentage of tumor involvement (PTI) along with pathologic Gleason Score (pGS). Completely unilateral cancers were identified in 254 (18.3%) patients, and in 39% cases of them the signs of clinically significant PCa were revealed. The majority of unilateral tumors (72%) were low volume with a PTI of ≤5. This study suggests that only a select group of men diagnosed with PCa have completely unilateral cancers that would be amenable to focal ablation therapy targeting 1 lobe. Further study is needed to develop predictive models for those patients likely to have small, unilateral cancers that may be amenable to focal therapy.
CatalonaW. J., SouthwickP. C., SlawinK. M., PartinA. W., BrawerM. K., FlaniganR. C., PatelA., RichieJ. P., WalshP. C., ScardinoP. T., LangeP. H., GasiorG. H., LovelandK. G., BrayK. R.Comparison of Percent Free PSA, PSA Density, and Age-specific PSA Cutoffs for Prostate Cancer Detection and Staging. Urology56, 255–260 (2000).
2.
CooperbergM. R., MoulJ. W., CarrollP. R.The Changing Face of Prostate Cancer. J Clin Oncol23, 8146–8151(2005).
3.
Boccon-GibodL. M., DumonceauO., ToublancM., RaveryV., Boccon-GibodL. A.Micro-focal Prostate Cancer: A Comparison of Biopsy and Radical Prostatectomy Specimen Features. Eur Urol48, 895–899 (2005).
4.
D'AmicoA. V., MoulJ., CarrollP. R., SunL., LubeckD., ChenM. H.Cancer-specific Mortality After Surgery or Radiation for Patients with Clinically Localized Prostate Cancer Managed During the Prostate-specific Antigen Era. J Clin Oncol21, 2163–2172 (2003).
5.
OnikG., NarayanP., VaughanD., DineenM., BrunelleR.Focal “Nerve-sparing” Cryosurgery for Treatment of Primary Prostate Cancer: A New Approach to Preserving Potency. Urology60, 109–114 (2002).
6.
BostwickD. G., KindrachukR. W., RouseR. V.Prostatic Adenocarcinoma with Endometrioid Features. Clinical, Pathologic, and Ultrastructural Findings. Am J Surg Pathol9, 595–609 (1985).
7.
GardnerT. A., LemerM. L., SchlegelP. N., WaldbaumR. S., VaughanE. D.Jr., SteckelJ.Microfocal Prostate Cancer: Biopsy Cancer Volume Does Not Predict Actual Tumour Volume. Br J Urol81, 839–843 (1998).
8.
DjavanB., RemziM., MarbergerM.When to Biopsy and When to Stop Biopsying. Urol Clin North Am30, 253–262 (2003).
9.
EpsteinJ. I., PotterS. R.The Pathological Interpretation and Significance of Prostate Needle Biopsy Findings: Implications and Current Controversies. J Urol166, 402–410 (2001).
10.
ChengL., JonesT. D., PanC. X., BarbarinA., EbleJ. N., KochM. O.Anatomic Distribution and Pathologic Characterization of Smallvolume Prostate Cancer (<0.5 ml) in Whole-mount Prostatectomy Specimens. Mod Pathol18, 1022–1026 (2005).
11.
AroraR., KochM. O., EbleJ. N., UlbrightT. M., LiL., ChengL.Heterogeneity of Gleason Grade in Multifocal Adenocarcinoma of the Prostate. Cancer100, 2362–2366 (2004).
12.
NoguchiM., StameyT. A., McNealJ. E., NolleyR.Prognostic Factors for Multifocal Prostate Cancer in Radical Prostatectomy Specimens: Lack of Significance of Secondary Cancers. J Urol.170, 459–463 (2003).
13.
ScwartzG. F., VeronesiU., CloughK. B., DixonM. J., FentimanI. S., Heywang-KobrunnerS. H.Consensus Conference on Breast Conservation. J Am Coll Surg203, 199–207 (2006).
Boccon-GibodL. M., de LongchampsN. B., ToublancM., Boccon-GibodL. A., RaveryV.Prostate Saturation Biopsy in the Reevaluation of Microfocal Prostate Cancer. J Urol176, 961–963 (2006).
16.
EpsteinJ. I., SandersonH., CarterH. B., ScharfsteinD. O.Utility of Saturation Biopsy to Predict Insignificant Cancer at Radical Prostatectomy. Urology66, 356–360 (2005).
17.
MassonP., PrepelicaK. L., LambertE. H., McKiernanJ. M., BensonM. C., OlssonC. A., KatzA. E.Focal Cryosurgery: Encouraging Health Outcomes for Unifocal Prostate Cancer. J Urol173 (suppl), 179 (Abstract #658) (2005).
18.
WeraheraP. N., MillerG. J., TorkkoK., CrawfordE. D., StewartJ. S., DeantoniE. P., MillerH. L., LuciaM. S.Biomorphometric Analysis of Human Prostatic Carcinoma by Using Three-dimensional Computer Models. Hum Pathol35, 798–807 (2004).
19.
PolascikT. J., NosnikI., MayesJ., MouravievV.Short-term Cancer Control After Primary Cryosurgical Ablation fro Clinically Localized Prostate Cancer using Third Generation Cryothechnology. Urology66, in press (2006).
20.
BarberT., PansareV., NikolavskyD., PontesE., SakrW., CherM.Pathologic Characteristics of Contralateral Prostate Cancer Among Patients with a Single Positive Core. J Urol175 (suppl), 507 (Abstract#1573) (2006).
21.
StameyT. A., DonaldsonA. N., YemotoC. E., McNealJ. E., SozenS., GillH.Histological and Clinical Findings in 896 Consecutive Prostates Treated Only with Radical Retropubic Prostatectomy: Epidemiologic Significance of Annual Changes. J Urol160, 2412–2417 (1998).
22.
MiyakeH., SakaiI., HaradaK., HaraI., EtoH.Prediction of Potentially Insignificant Prostate Cancer in Men Undergoing Radical Prostatectomy for Clinically Organ-confined Disease. Int J Urol12, 270–274 (2005).
23.
McNealJ. E., BostwickD. G., KindrachukR. A., RedwineE. A., FreihaF. S., StameyT. A.Patterns of Progression in Prostate Cancer. Lancet1, 60–63 (1986).
24.
BostwickD. G., GrignonD. J., HammondM. E., AminM. B., CohenM., CrawfordD., GospadarowiczM., KaplanR. S., MillerD. S., MontironiR., PajakT. F., PollackA., SrigleyJ. R., YarbroJ. W.Prognostic Factors in Prostate Cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med124, 995–1000 (2000).
25.
CarrollP. R., PrestiJ. C.Jr., SmallE., RoachM., 3rd. Focal Therapy for Prostate Cancer 1996: Maximizing Outcome. Urology49, 84–94 (1997).
26.
VerhagenP. C., TilanusM. G., de WegerR. A., van MoorselaarR. J., van den TweelJ. G., BoonT. A.Prognostic Factors in Localised Prostate Cancer with Emphasis on the Application of Molecular Techniques. Eur Urol41, 363–371 (2002).
27.
KonishiN., NakamuraM., KishiM., IshidaE., ShimadaK., MatsuyoshiS., NagaiH., EmiM.Genetic Mapping of Allelic Loss on Chromosome 6q Within Heterogeneous Prostate Carcinoma. Cancer Sci94, 764–768 (2003).
28.
OhonM., EashamJ., KohH., KurolwaK., SlawinK., WheelerT. M., ScardinoP. T.Is Focal Therapy Reasonable in Patients with Early Stage Prostate Cancer (CAP)-An Analysis of Radical Prostatectomy (RP) Specimens. J Urol175 (suppl), 507 (Abstract #1574) (2006).
